A A A  Font Size

retinal disorders

Learn about retinal disorders including the symptoms and treatment.

Located conveniently in South Bend, Kokomo, and Fort Wayne, The Retinal Institute offers specialized consultative care and treatment throughout Indiana for retinal diseases and conditions. The Retinal Institute is committed to providing the latest in skilled care, state-of-the-art technology, and innovative therapies to help improve our patients’ vision and their lives. Part of that commitment lies in working cohesively with patients’ optometrists and other health care professionals to achieve and maintain proactive, ongoing treatment programs.

Our board certified eye surgeon, Scott C. Richards, M.D., is a retinal specialist and brings years of experience to The Retinal Institute. A graduate of the University of Utah School of Medicine, Dr. Richards has focused his practice on the diagnosis and treatment of vitreoretinal diseases, including diabetic retinopathy, macular degeneration, epiretinal membrane, macular holes, retinal detachment, and other disorders of the retina and/or vitreous. Dr. Richards is well-regarded in the medical community and is known for his research in glaucoma and ocular hypertension, severe vitreous hemorrhage, twin eye diseases, and retinopathy of prematurity. The medical and surgical staff of The Retinal Institute is dedicated, experienced, and empathetic to patients’ needs. They understand the anxiety and stress of vision problems and seek to make each visit to The Retinal Institute as comfortable as possible.

The Retinal Institute’s main goal is to compassionately and effectively enhance the lives of patients and their families by utilizing the latest in technology and treatment, providing skilled staff that understands patients’ and their families’ needs and concerns, and by facilitating the exchange of information between health care professionals, thereby working collectively to manage patients’ eye health conditions.

Giving Back


Each year, The Retinal Institute raises money to support Foundation Fighting Blindness. Read more...

News
  • Jun 17, 2015

    A clinical trial for a retinitis pigmentosa (RP) stem-cell therapy has received authorization to launch from the U.S. Food and Drug Administration (FDA). Sixteen people will be enrolled in the safety-focused study, which will also monitor changes in visual acuity and retinal sensitivity. Trial participants will receive injections of 500,000 or one million cells.
Let Us Help
Locations
Site designed and developed by King & Knight